D. Arber, A. Orazi, and R. Hasserjian, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-2405, 2016.
DOI : 10.1182/blood-2016-03-643544

U. Germing, M. Lauseker, and B. Hildebrandt, Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study, Leukemia, vol.89, issue.6, pp.1286-1292, 2012.
DOI : 10.1182/blood-2011-01-330126

A. List, G. Dewald, and J. Bennett, Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion, New England Journal of Medicine, vol.355, issue.14, pp.1456-1465, 2006.
DOI : 10.1056/NEJMoa061292

P. Fenaux, A. Giagounidis, and D. Selleslag, A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q, Blood, vol.118, issue.14, pp.3765-3776, 2011.
DOI : 10.1182/blood-2011-01-330126

R. Tehranchi, P. Woll, and K. Anderson, Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission, New England Journal of Medicine, vol.363, issue.11, pp.1025-1037, 2010.
DOI : 10.1056/NEJMoa0912228

M. Jädersten, L. Saft, and A. Smith, Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression, Journal of Clinical Oncology, vol.29, issue.15, pp.1971-1979, 2011.
DOI : 10.1200/JCO.2010.31.8576

R. Bejar, K. Stevenson, and O. Abdel-wahab, Clinical Effect of Point Mutations in Myelodysplastic Syndromes, New England Journal of Medicine, vol.364, issue.26, pp.2496-2506, 2011.
DOI : 10.1056/NEJMoa1013343

M. Walter, D. Shen, and L. Ding, Clonal Architecture of Secondary Acute Myeloid Leukemia, New England Journal of Medicine, vol.366, issue.12, pp.1090-1098, 2012.
DOI : 10.1056/NEJMoa1106968

C. Scharenberg, V. Giai, and A. Pellagatti, Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations, Haematologica, vol.102, issue.3, pp.498-508, 2017.
DOI : 10.3324/haematol.2016.152025

M. Mossner, J. J. Wittig, and J. , Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure, Blood, vol.128, issue.9, pp.1246-1259, 2016.
DOI : 10.1182/blood-2015-11-679167
URL : http://www.bloodjournal.org/content/bloodjournal/128/9/1246.full.pdf

P. Silva-coelho, L. Kroeze, and K. Yoshida, Clonal evolution in myelodysplastic syndromes, Nature Communications, vol.51, p.15099, 2017.
DOI : 10.1182/blood-2014-04-571018

B. Cheson, P. Greenberg, and J. Bennett, Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, vol.108, issue.2, pp.419-425, 2006.
DOI : 10.1182/blood-2005-10-4149

V. Grossmann, A. Roller, and H. Klein, Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications, The Journal of Molecular Diagnostics, vol.15, issue.4, pp.473-484, 2013.
DOI : 10.1016/j.jmoldx.2013.03.003

D. Landau, S. Carter, and P. Stojanov, Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia, Cell, vol.152, issue.4, pp.714-726, 2013.
DOI : 10.1016/j.cell.2013.01.019

T. Wong, G. Ramsingh, and A. Young, Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia, Nature, vol.83, issue.7540, pp.552-555, 2015.
DOI : 10.1021/ac202028g